• 全国 [切换]
  • 二维码
    错改网

    手机WAP版

    手机也能找商机,信息同步6大终端平台!

    微信小程序

    微信公众号

    当前位置: 首页 » 行业新闻 » 热点新闻 » 正文

    【中国日报】Osteoarthritis treatment IP case solved in court

    放大字体  缩小字体 发布日期:2021-06-10 15:43:39   浏览次数:692  发布人:d50e****  IP:124.223.189***  评论:0
    导读

    China's top court solved a long-term intellectual property case between two technological companies on Wednesday, coinciding with Constitution Day, demonstrating the country's judicial determination

    China's top court solved a long-term intellectual property case between two technological companies on Wednesday, coinciding with Constitution Day, demonstrating the country's judicial determination and effort to promote scientific and technological innovation.

    Thanks to the effort of the Supreme People's Court, three scientific researchers from two corporations settled a patent dispute, agreeing to continue working together on a pharmaceutical research and development study.

    The patent involved in the case focuses on healthcare, which is a drug for the treatment of osteoarthritis and the method for making it, according to the top court.

    In 2018, Hu Yong, Yu Yin and Wang Gang returned from studying abroad and jointly founded a technology in Shenzhen, Guangdong province, with the goal of promoting the research and transformation of osteoarthritis technology in China.

    In September 2019, Hu established another company. In June 2021, Hu's company applied for the patent involved in the case, which was authorized by the IP administration in October that year.

    Arguing that the patent was Hu's invention in the original company, Wang and Yu initiated a lawsuit at the Shenzhen Intermediate People's Court, requesting judges to identify the ownership of the patent.

    However, the request was rejected by the intermediate court, leading to an appeal by Wang and Yu to the top court.

    While facing the patent lawsuit, the two technology companies, where the three litigants work, were also involved in other disputes, including those on technical secrets and contract, the top court said.

    After learning about the trio's story and visiting the two companies, the top court decided to collectively solve all of their lawsuits together, "so as to help them focus more on scientific and technological innovation, instead of spending their energy on litigation," it added.

    The three litigants eventually agreed to the judicial decision to no longer confront in litigation and pledged to continue their research in the field of biomedicine.

    "Solving the disputes for the researchers through mediation stimulates creative vitality and encourages innovators," the top court said. "It will also be conducive to promoting the country's growth in technology and advancing industrial integration and development."

    来源:中国日报

    记者:曹音

    编辑:时雨萌

    nload="this.removeAttribute('width'); this.removeAttribute('height'); this.removeAttribute('onload');" />


    不推荐电脑端访问(用户少)
    请微信扫一扫,查看完整信息(记得微信收藏)
     
    (文/匿名(若涉版权问题请联系我们核实发布者) / 非法信息举报 / 删稿)
    打赏
    免责声明
    • 
    本文为昵称为 d50e**** 发布的作品,本文仅代表发布者个人观点,本站未对其内容进行核实,请读者仅做参考,如若文中涉及有违公德、触犯法律的内容,一经发现,立即删除,发布者需自行承担相应责任。涉及到版权或其他问题,请及时联系我们154208694@qq.com删除,我们积极做(权利人与发布者之间的调停者)中立处理。郑重说明:不 违规举报 视为放弃权利,本站不承担任何责任!
    有个别老鼠屎以营利为目的遇到侵权情况但不联系本站或自己发布违规信息然后直接向本站索取高额赔偿等情况,本站一概以诈骗报警处理,曾经有1例诈骗分子已经绳之以法,本站本着公平公正的原则,若遇 违规举报 我们100%在3个工作日内处理!
    0 条相关评论
     

    (c)2008-现在 cuogai.com All Rights Reserved.